Further Safety Data on the Pfizer SARS-CoV-2 mRNA Vaccine

Observational analysis following mass vaccination across Israel found minimal systemic adverse effects.

Multiple studies have shown that the SARS-CoV-2 mRNA vaccines are effective (NEJM JW Infect Dis Apr 2021 and N Engl J Med 2021 Feb 24; [e-pub]; NEJM JW Infect Dis Sep 2021 and JAMA 2021 Jul 12; [e-pub]; NEJM JW Infect Dis Sep 2021 and Ann Intern Med 2021 Jul 20; [e-pub]), but hesitant individuals continue to raise concerns about adverse reactions as a justification for refusing vaccination. To better define the Pfizer vaccine's safety profile, investigators used observational data from the largest health care organization in Israel. They assessed the likelihood of adverse events occurring within 42 days after immunization by comparing 884,828 vaccinated individuals with matched unvaccinated controls. To estimate the adverse effects of SARS-…

Reviewing Author

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Further Safety Data on the Pfizer SARS-CoV-2 mRNA Vaccine

Topics

Reviewing Author